1. A Split Luciferase Complementation Assay for the Quantification of β-Arrestin2 Recruitment to Dopamine D 2 -Like Receptors.
- Author
-
Forster L, Grätz L, Mönnich D, Bernhardt G, and Pockes S
- Subjects
- Animals, HEK293 Cells, Humans, Kinetics, Ligands, Luciferases analysis, Luciferases genetics, Protein Binding, Receptors, Dopamine D2 agonists, Receptors, Dopamine D2 analysis, beta-Arrestin 2 agonists, beta-Arrestin 2 analysis, Biological Assay methods, Drug Evaluation, Preclinical methods, Luciferases metabolism, Receptors, Dopamine D2 metabolism, beta-Arrestin 2 metabolism
- Abstract
Investigations on functional selectivity of GPCR ligands have become increasingly important to identify compounds with a potentially more beneficial side effect profile. In order to discriminate between individual signaling pathways, the determination of β-arrestin2 recruitment, in addition to G-protein activation, is of great value. In this study, we established a sensitive split luciferase-based assay with the ability to quantify β-arrestin2 recruitment to D
2long and D3 receptors and measure time-resolved β-arrestin2 recruitment to the D2long receptor after agonist stimulation. We were able to characterize several standard (inverse) agonists as well as antagonists at the D2long R and D3 R subtypes, whereas for the D4.4 R, no β-arrestin2 recruitment was detected, confirming previous reports. Extensive radioligand binding studies and comparisons with the respective wild-type receptors confirm that the attachment of the Emerald luciferase fragment to the receptors does not affect the integrity of the receptor proteins. Studies on the involvement of GRK2/3 and PKC on the β-arrestin recruitment to the D2long R and D3 R, as well as at the D1 R using different kinase inhibitors, showed that the assay could also contribute to the elucidation of signaling mechanisms. Its broad applicability, which provides concentration-dependent and kinetic information on receptor/β-arrestin2 interactions, renders this homogeneous assay a valuable method for the identification of biased agonists.- Published
- 2020
- Full Text
- View/download PDF